72. 下垂体性ADH分泌異常症 Disease details / Clinical trials / Drug dev / DR info

Arginine
   Arima Hiroshi
      2022   -   JPRN-jRCTs041220082   -
C03xa01
   Department of Medical Research
      2014   Phase 2   EUCTR2013-003800-38-DK   Denmark
   University Clinic in Nephrology and Hypertension, Department of Medical Research
      2014   -   EUCTR2014-001973-15-DK   Denmark
CRH administration
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2021   Phase 4   NCT04902235   Spain
Desmopressin intranasal
   Ferring Pharmaceuticals
      2011   Phase 3   NCT01280188   Japan
Desmopressin oral melt
   Ferring Pharmaceuticals
      2011   Phase 3   NCT01280188   Japan
Empagliflozin
   University Hospital, Basel, Switzerland
      2016   Phase 2/Phase 3   NCT02874807   Switzerland
Empagliflozin 25 MG
   University Hospital, Basel, Switzerland
      2021   Phase 4   NCT04447911   Switzerland
Empagliflozin 25MG
   University Hospital, Basel, Switzerland
      2017   Phase 2/Phase 3   NCT03202667   Switzerland
Empagliflozin 25MG TBL
   University Hospital, Basel, Switzerland
      2016   Phase 2/Phase 3   NCT02729766   Switzerland
Fluid restriction
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2010   Phase 3   NCT01227512   United States
GLP1-RA (exenatide) administration
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2021   Phase 4   NCT04897802   Spain
Induced hypotonic hyponatremia - siad model
   University Hospital, Basel, Switzerland
      2016   Phase 2/Phase 3   NCT02729766   Switzerland
Intranasal OXT
   University Hospital, Basel, Switzerland
      2024   Phase 2   NCT06036004   Netherlands;Switzerland
IRM
   Assistance Publique Hopitaux De Marseille
      2025   -   NCT06604975   France
Iupac
   Sanofi-Synthelabo Research
      2004   Phase 3   EUCTR2004-002349-11-ES   Spain
Mdma
   University Hospital, Basel, Switzerland
      2025   -   NCT06789705   Switzerland
Measure OF arginine-stimulated copeptin
   Assistance Publique Hopitaux De Marseille
      2025   -   NCT06604975   France
Measure OF basal copeptin level
   Assistance Publique Hopitaux De Marseille
      2025   -   NCT06604975   France
Melatonin
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2022   -   NCT05319301   Spain
Oxytocin nasal spray
   Elizabeth Austen Lawson
      2023   Phase 1   NCT04789148   United States
   University Hospital, Basel, Switzerland
      2025   Phase 2   NCT06808516   Switzerland
      2025   Phase 2   NCT06676774   Switzerland
Samsca
   Department of Medical Research
      2014   Phase 2   EUCTR2013-003800-38-DK   Denmark
      2012   Phase 2   EUCTR2012-001169-33-DK   Denmark
   Otsuka Pharmaceutical Co., Ltd.
      2021   -   NCT04790175   Japan
   University Clinic in Nephrology and Hypertension, Department of Medical Research
      2014   -   EUCTR2014-001973-15-DK   Denmark
Samsca*10CPR 15MG
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2012   -   EUCTR2012-004071-39-IT   Italy
Satavaptan
   Sanofi
      2008   Phase 3   NCT00728091   United States
      2001   Phase 2   NCT00032734   Belgium;Canada;France;Germany;Hungary;United States
   sanofi-aventis recherche et développement
      2008   -   EUCTR2007-007941-10-HU   Belgium;France;Germany;Hungary
      2008   Phase 3   EUCTR2007-007941-10-FR   Belgium;France;Germany;Hungary
      2008   -   EUCTR2007-007941-10-DE   Belgium;France;Germany;Hungary
      2008   -   EUCTR2007-007941-10-BE   Belgium;France;Germany;Hungary
SR121463B
   Sanofi
      2005   Phase 3   NCT00264914   Australia;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Russian Federation;Switzerland;United States
      2004   Phase 3   NCT00264927   Belgium;Brazil;Canada;Croatia;Germany;Hong Kong;Hungary;Netherlands;Portugal;Spain;United States
      2001   Phase 2   NCT00032734   Belgium;Canada;France;Germany;Hungary;United States
   Sanofi-Synthelabo Research
      2005   -   EUCTR2004-005239-25-HU   Germany;Hungary;Spain
      2005   Phase 3   EUCTR2004-005239-25-ES   Germany;Hungary;Spain
      2005   -   EUCTR2004-005239-25-DE   Germany;Hungary;Spain
      2005   -   EUCTR2004-003985-14-HU   Denmark;Hungary;Sweden
      2005   Phase 3   EUCTR2004-003985-14-BE   Belgium;Denmark;Hungary;Sweden
      2004   Phase 3   EUCTR2004-002349-11-ES   Spain
   sanofi-aventis recherche & développement
      2005   -   EUCTR2004-003985-14-SE   Denmark;Hungary;Sweden
      2005   -   EUCTR2004-003985-14-DK   Denmark;Hungary;Sweden
   sanofi-aventis recherche et développement
      2008   -   EUCTR2007-007941-10-HU   Belgium;France;Germany;Hungary
      2008   Phase 3   EUCTR2007-007941-10-FR   Belgium;France;Germany;Hungary
      2008   -   EUCTR2007-007941-10-DE   Belgium;France;Germany;Hungary
      2008   -   EUCTR2007-007941-10-BE   Belgium;France;Germany;Hungary
Tolvaptan
   Department of Medical Research
      2014   Phase 2   EUCTR2013-003800-38-DK   Denmark
      2012   Phase 2   EUCTR2012-001169-33-DK   Denmark
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
      2012   -   EUCTR2012-004071-39-IT   Italy
   King's College Hospital NHS Trust
      2024   -   NCT06171100   United Kingdom
   Otsuka Frankfurt Research Institute GmbH
      2010   -   NCT01228682   Denmark;Germany;Italy;Norway;Spain;Sweden;United Kingdom
   Otsuka Pharmaceutical Co., LTD.
      2017   Phase 3   JPRN-jRCT2080223457   Japan
   Otsuka Pharmaceutical Co., Ltd.
      2021   -   NCT04790175   Japan
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2013   Phase 1/Phase 2   NCT02009878   Czech Republic;Denmark;Germany;Hungary;Spain;Sweden;United Kingdom
      2010   Phase 3   NCT01227512   United States
      2003   Phase 3   NCT00201994   Germany
      2003   Phase 3   NCT00072683   United States
   Polderman, Kees, H., MD, PhD
      2015   -   NCT02545114   United States
   University Clinic in Nephrology and Hypertension, Department of Medical Research
      2014   -   EUCTR2014-001973-15-DK   Denmark
Tolvaptan IN euvolemic hyponatremia
   NYU Langone Health
      2011   -   NCT01425125   United States
Tolvaptan oral tablet
   Otsuka Pharmaceutical Co., Ltd.
      2017   Phase 3   NCT03048747   Japan
Urea
   Helbert Rondon Berrios, MD, MS
      2021   Phase 2   NCT04588207   United States
   University Hospital, Grenoble
      2020   -   NCT04552873   France
Water reduction AT home
   Assistance Publique Hopitaux De Marseille
      2025   -   NCT06604975   France